Health Care [ 11/12 ] | Pharmaceuticals [ 60/74 ]
NASDAQ | Common Stock
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir.
Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.40 Increased by +14.89% | -0.29 Decreased by -38.12% |
| Nov 7, 24 | -0.37 Increased by +7.50% | -0.49 Increased by +24.49% |
| Aug 7, 24 | -0.48 Decreased by -41.18% | -0.76 Increased by +36.84% |
| May 14, 24 | -0.75 Decreased by -74.42% | -0.61 Decreased by -22.95% |
| Feb 28, 24 | -0.47 Decreased by -14.63% | -0.50 Increased by +6.00% |
| Nov 8, 23 | -0.40 Decreased by -300.00% | -0.48 Increased by +16.67% |
| Aug 8, 23 | -0.34 Increased by +10.53% | -0.47 Increased by +27.66% |
| May 8, 23 | -0.43 Increased by +15.69% | -0.48 Increased by +10.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -33.54 M Increased by +14.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -31.15 M Increased by +6.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -40.52 M Decreased by -43.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -63.17 M Decreased by -78.11% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -39.16 M Decreased by -13.75% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -33.14 M Decreased by -310.89% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -28.18 M Increased by +10.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -35.47 M Increased by +15.51% | Decreased by N/A% Decreased by N/A% |